We screened 117 breast tumour samples in Chinese females for mutations in the breast cancer 1 (BRCA1) gene and identified a novel mutation in the 5´ untranslated region (5´ UTR) in two patients with grade III infiltrating ductal breast carcinoma. We examined whether this 5´ UTR mutation affected the translational efficiency of BRCA1 protein.
Introduction
The incidence of breast cancer is high among women, including both hereditary (5 -10%) and sporadic forms. 1 Recently, the incidence and mortality of the disease have markedly increased in the Chinese population, especially in some large cities. The breast cancer 1 (BRCA1) gene is associated with 10% of breast and ovarian cancers, 2 and BRCA1 gene mutations have been identified in up to 80% of hereditary breast and ovarian cancers. 3 In addition, somatic mutations and loss of heterozygosity may result in inactivation of the BRCA1 gene in at least a small number of ovarian cancers 4 and downregulation of BRCA1 gene expression is frequently found in sporadic breast cancers in the absence of any direct mutation in the coding region. 5 The majority of the control of protein J Wang, C Lu, D Min et al. Mutation in the 5´ UTR of BRCA1 in Chinese breast cancer patients translation occurs at the level of translation initiation, thus implicating the 5ú ntranslated region (5´ UTR) as a major site of translational regulation. 6 Sequences flanking the AUG start codon can modulate the scanning activity of the 40S ribosomal subunit and its ability to initiate translation. 7 Mutations in the 5´ UTR that weaken adherence to the Kozak consensus motif, a sequence that directs ribosomes to initiate protein synthesis from mRNA, negatively affect translation initiation. 8 Germ-line or somatic mutations that cause disease by up-or downregulating the efficiency of mRNA translation have been extensively identified, which has led to an awareness of translational pathophysiology as a novel molecular mechanism underlying human disease. 9 As already documented in diseases other than cancer, 10 -12 experimental transversion of the consensus sequence at the -3 position of the BRCA1 initiation sequence strongly decreases translation efficiency to 30% of the normal synthesis of the wild-type BRCA1 protein.
Positions -2 and -1 have been suggested to have a cooperative effect on translation in both eucaryotes and procaryotes. 13 Reductions in both BRCA1 mRNA and BRCA1 protein are frequently observed in sporadic breast and ovarian cancers. 14 Signori et al. 15 reported a somatic mutation in the 5´ UTR at position -3 of the BRCA1 gene in sporadic breast cancer, which caused downregulation of translation efficiency. Moreover, Liu et al. 16 reported that mutations in the 5Ú TR of BRCA1 made a second start codon act as an alternative initiation site and resulted in a protein that lacked the first 17 amino acids of the wild-type BRCA1 protein.
Case report BREAST CANCER SAMPLES
Samples of breast cancer tissue have been collected by the AnHui and ShanXI Province Tumour Hospital (Bengbu, China) since 1970. Two female cases diagnosed with grade III infiltrating ductal carcinoma of the breast were selected from these samples for study, following successful retrospective screening of 117 Chinese patients for BRCA1 gene mutations using denaturing high performance liquid chromatography (DHPLC) as described below. This study did not require ethical approval or individual informed patient consent.
The first female patient was 40 years old and had found a lump on the breast 10 years previously. She was diagnosed with a grade III infiltrating ductal carcinoma of the breast and underwent mastectomy, ancillary lymph node resection, radiotherapy, and six cycles of standard adjuvant chemotherapy. The tumour recurred after 10 months and the patient died 1 year later.
The second female patient was 45 years old and had been initially diagnosed with breast cystic hyperplasia and underwent irregular treatment with traditional Chinese medicine. She was subsequently diagnosed with a grade III infiltrating ductal carcinoma of the breast and was treated as described for the first patient, above. The tumour recurred after 10 months and the patient died 2 years later.
VERIFICATION OF GENE MUTATIONS BY DHPLC AND SEQUENCING
Retrospective screening of 117 Chinese patients for BRCA1 gene mutations used DHPLC. The first stage was to extract DNA from breast cancer tissue samples using standard phenol/chloroform extraction protocols. 17 Polymerase chain reaction (PCR) products were denatured at 95 ºC and gradually cooled to room temperature to enable efficient formation of heteroduplexes between DNA fragments in order to identify Mutation in the 5´ UTR of BRCA1 in Chinese breast cancer patients gene mutations. The DHPLC was carried out in a transgenomic wave DNA fragment analysis system according to the method of Gross et al. 18 at a temperature of 55 ºC. Genomic DNA was re-amplified with DHPLC primers and, after purification, DNA sequence changes were evaluated by direct sequencing in both directions. After treatment with ethanol, cycle sequencing products were analysed on an ABI PRISM ® 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
DUAL-LUCIFERASE ACTIVITY ASSAYS
In order to evaluate whether the A to T mutation at position 118 of the BRCA1 gene that was identified in our two breast cancer patients was able affect protein translation, we produced mutated 5´ UTR and wild-type 5´UTR constructs for transfection and expression in cultured cells. For this purpose, the 19-nucleotide sequences that encoded the wild-type short (wt short) and the mutated short (mut short) chimeric mRNAs of the BRCA1 translational initiation sequence were cloned downstream of the SV40 promoter region of the pGL3 promoter vector (Promega, Madison WI, USA) ( Fig. 1) . A 0.5 µg aliquot of each of the resulting constructs (pGLwt , pGLmut or pGL3) was transiently transfected separately into human HEK293 cells, together with 0.2 µg of 
SEMI-QUANTITATIVE RT-PCR ANALYSIS
cDNAs were generated from 1 µg of mRNA isolated from cells transiently transfected with the three different constructs using oligo The luciferase-specific primer sequences generated an expected amplification product of 147 base pairs (bp): sense, 5´-GCATACGA CGATTCTGTGA-3´; anti-sense, 5´-TACG CCCTGGTTCCTG-3´. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH)specific primer sequences generated an expected amplification product of 200 bp: sense, 5´-CAAAGTTGTCATGGATGACC-3´; anti-sense, 5´-CCATGGAGAAGGCTGGGG-3´.
The RT-PCR amplifications were carried out as follows: 20 -35 cycles of 1 min at 94 ºC, 1 min at 58 ºC and 1 min at 72 ºC, followed by 10 min at 72 ºC. A 10 µl aliquot of the amplification product was analysed by electrophoresis on a 2% agarose gel.
IMMUNOHISTOCHEMICAL ANALYSIS
Immunohistochemistry was performed using a streptavidin-biotin-peroxidase technique with antibodies to BRCA1 protein (D9 monoclonal mouse antibody raised against a peptide mapping at the C-terminus of the BRCA1 mRNA, Santa Cruz dilution 1:100). Sections (5 mm) of paraffin-embedded tissue samples were deparaffinized and rehydrated through a series of graded alcohols (95%, 75%, 50%, 30% diluted with double-distilled water). Endogenous peroxidase activity was blocked by 30-min incubation in 3% hydrogen peroxide-methanol and washed in phosphate-buffered saline (PBS). The slides were heated in citrate buffer for 5 -10 min in a microwave oven, rinsed in PBS at room temperature and incubated for 20 -30 min with A2 blocking serum. After washing, the sections were incubated for 60 -120 min with primary antibodies and incubated for 30 min with biotinylated horse anti-mouse IgG immunoglobulin (Dako K0675; Dako, Glostrup, Denmark). The sections were incubated for 30 min with streptavidin peroxidase reagent and washed in PBS. The immunoperoxidase was visualized with 3amino-9-ethylcarbazole (AEC) (Dako AEC substrate K0696; Dako, Glostrup, Denmark). The sections were counterstained with Mayer's haematoxylin and overlaid with coverslips.
STATISTICAL ANALYSIS
The Stat View II program (Abacus Concepts Inc., Berkeley, CA, USA) was used for all statistical analyses. A P-value < 0.05 was considered to be statistically significant.
RESULTS
The nucleotide sequences of exon 2 of the BRCA1 gene from breast cancer samples from the two female patients were successfully amplified and analysed using DHPLC and J Wang, C Lu, D Min et al. Mutation in the 5´ UTR of BRCA1 in Chinese breast cancer patients sequenced (Fig. 2) . A 5´ UTR mutation was demonstrated for the first time in Chinese people ( Table 1) . It occurred at nucleotide 118 and involved two nucleotides 5´ of the AUG initiation codon within a Kozak consensus motif for the start of protein translation.
The reporter plasmids containing both the mutated and wild-types of the 5´ UTR translational initiation sequence were constructed successfully ( Fig. 
Patient
Mutation SNP 1) . The results demonstrated that the construct with the mutated 5´ UTR sequence produced significantly less (P < 0.05) luciferase activity compared with the wildtype 5´ UTR for BRCA1 (Fig. 3) . In order to establish if the observed difference in luciferase activity between cells transfected with the wild-type or mutant BRCA1 5´ UTR was caused by a reduction in translation efficiency of the mutant form, we analysed the levels of chimeric mRNA in the transfected cells. Total RNA was extracted from the cells and analysed by semiquantitative RT-PCR for the expression of J Wang, C Lu, D Min et al. Mutation in the 5´ UTR of BRCA1 in Chinese breast cancer patients luciferase mRNA. No significant differences at the mRNA level were observed, indicating that transcription efficiency and RNA stability were the same for the two chimeric mRNAs (Fig. 4) .
Female age 40 years 118 A to T 2201 T to C 2430 T to C Female age 45 years 118 A to T 105 T to C
Immunohistochemical examination of breast tumour tissue from the two breast cancer patients with the 5´ UTR BRCA1 gene mutation were compared with samples taken from Chinese breast cancer patients without the mutation in order to elucidate the pathological nature of the expression of the BRCA1 protein. Figure 5 indicates less BRCA1 protein expression (less staining) in the two patients with the 5´ UTR BRCA1 gene mutation than in patients without the mutation.
Discussion
We have identified a novel mutation in two patients with breast cancer at position -2 from AUG in the 5´ UTR of the BRCA1 gene, within a Kozak consensus motif for the start of protein translation, resulting in reduced protein translation. Other mutations and polymorphisms of the two patients had little or no effect on BRCA1 gene function. Other published literature has shown the great majority of studied families with hereditary susceptibility to breast and ovarian cancer to have mutations in the protein coding regions. 19 -21 It is now clear that mutations in the 5´ UTR are implicated in the development of some diseases. 6,22 -25 The initiation phase of protein synthesis sets the reading frame that is maintained throughout the whole of the translation process, and regulates the level of initiation and the translation efficiency. Initiation sites in eucaryotic mRNAs are reached via a scanning mechanism that usually selects the translation start site at the nearest AUG codon to the 5´ end of the mRNA molecule. 7 The BRCA1 gene is associated with sporadic breast and ovarian cancer in terms of reduced expression; hence reduced levels of BRCA1 mRNA and protein are frequently observed in sporadic breast and ovarian cancers. 14, 26, 27 Conversely, over-expression of BRCA1 protein results in tumour growth inhibition. 28 The BRCA1 mRNA can be expressed from two different promoter regions, resulting in two alternative exons 1a and 1b. 29 The open-reading frame begins in exon 2, and, consequently, alternative transcription results in mRNAs with different 5´ UTRs. 29 BRCA1 mRNA containing the exon 1b transcript has been found in breast cancer tissues but not in normal mammary glands, where BRCA1 mRNA containing exon 1a is the predominant transcript. 29 Transcript 1b has been found to have a longer 5´ UTR with a more stable secondary structure as well as upstream AUG codons which, together, have been shown to contribute to a 10-fold reduction in translational efficiency of BRCA1b compared with BRCA1a. 29 These characteristics result in downregulation of BRCA1 protein translation in breast cancer cells and, consequently, abrogate the normal tumour growth inhibition associated with BRCA1.
Signori et al. 15 had reported a somatic mutation in BRCA1 at nucleotide position 117 in the 5´ UTR of the promoting region. By in vitro and in vivo molecular analysis, rather than pathology, they demonstrated that the mutation (G to C) downregulated the translational efficiency of the BRCA1 mRNA.
Our study has identified a novel mutation in the 5´ UTR of the BRCA1 gene by population-based retrospective screening for BRCA1 gene mutations in samples of breast cancer tissue from Chinese patients using DHPLC. We have demonstrated that a mutation at nucleotide position 118, two nucleotides 5´ of the AUG initiation codon in the 5´ UTR, downregulated expression of BRCA1 protein. Our novel findings provide additional information on the implications of mutations in the 5´ UTR for the development of some human diseases.
